- Home
- GOSS vs ALT Comparison
GOSS vs ALT Comparison
Compare GOSS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ALT
- Stock Information
- Founded
- GOSS 2015
- ALT 1997
- Country
- GOSS United States
- ALT United States
- Employees
- GOSS N/A
- ALT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- ALT Health Care
- Exchange
- GOSS Nasdaq
- ALT Nasdaq
- Market Cap
- GOSS 347.8M
- ALT 292.0M
- IPO Year
- GOSS 2019
- ALT N/A
- Fundamental
- Price
- GOSS $2.47
- ALT $3.83
- Analyst Decision
- GOSS Strong Buy
- ALT Strong Buy
- Analyst Count
- GOSS 4
- ALT 6
- Target Price
- GOSS $8.50
- ALT $17.40
- AVG Volume (30 Days)
- GOSS 3.1M
- ALT 3.0M
- Earning Date
- GOSS 08-05-2025
- ALT 08-12-2025
- Dividend Yield
- GOSS N/A
- ALT N/A
- EPS Growth
- GOSS N/A
- ALT N/A
- EPS
- GOSS N/A
- ALT N/A
- Revenue
- GOSS $40,237,000.00
- ALT $20,000.00
- Revenue This Year
- GOSS N/A
- ALT N/A
- Revenue Next Year
- GOSS $30.65
- ALT $761,880.20
- P/E Ratio
- GOSS N/A
- ALT N/A
- Revenue Growth
- GOSS N/A
- ALT N/A
- 52 Week Low
- GOSS $0.66
- ALT $2.90
- 52 Week High
- GOSS $2.65
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- ALT 51.79
- Support Level
- GOSS $2.38
- ALT $3.35
- Resistance Level
- GOSS $2.65
- ALT $3.66
- Average True Range (ATR)
- GOSS 0.15
- ALT 0.19
- MACD
- GOSS 0.03
- ALT 0.07
- Stochastic Oscillator
- GOSS 76.67
- ALT 86.18
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.